Emdogain gets CE marking as Class III device
This article was originally published in Clinica
Swedish company Biora's Emdogain has obtained the CE marking as a Medical Devices Directive Class III device for periodontal regeneration. One of the first such products to be regulated under the Directive, Emdogain made its European debut last week.
You may also be interested in...
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.